Loading patent…
AssigneesBiofactura, Inc., The Administrators of the Tulane Educational Fund
InventorsLuis M. BRANCO, Alexander MATSCHINER, Megan M. ILLICK, Darryl B. SAMPEY, Robert F. GARRY, Daniel G. BAUSCH, Joseph N. FAIR, Mary C. GUTTIERI, Kathleen A. CASHMAN, Russell B. WILSON, Peter C. KULAKOSKY, F. Jon GESKE
Estimating the term…
Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.
A polypeptide comprising an isolated protein selected from the group consisting of (a) a polypeptide consisting of the amino acid sequence of the ectodomain of Lassa virus (LASV) glycoprotein 1 (GP1) optionally fused at the C-terminus thereof to an amino acid sequence consisting of the transmembrane domain of LASV glycoprotein 2 (GP2), (b) a polypeptide consisting of the ectodomain of LASV GP2, and (c) a full length, soluble recombinant Lassa virus nucleocapsid protein (LASV NP) fused with maltose binding protein (MBP).
(canceled)
(canceled)
10-17. (canceled)
Dependencies are inferred from the claim text.